Literature DB >> 25863695

Preeclampsia in autologous and oocyte donation pregnancy: is there a different pathophysiology?

Lisa E E L O Lashley1, Aletta Buurma2, Godelieve M J S Swings3, Michael Eikmans3, Jacqueline D H Anholts3, Jaap A Bakker4, Frans H J Claas3.   

Abstract

Oocyte donation (OD) is a specific method of artificial reproductive technology that is accompanied by a higher risk of preeclampsia during pregnancy. The pathophysiological mechanism underlying preeclampsia in OD pregnancies is thought to differ from preeclampsia in autologous pregnancies. As preeclampsia in autologous pregnancies is suggested to be associated with complement activation, we studied C4d deposition, circulating complement components and placental complement regulatory proteins in preeclamptic OD pregnancies. Women with uncomplicated and preeclamptic pregnancies after OD or spontaneous conception were selected. We stained the placentas for C4d, marker for complement activation, measured complement factors C1q, C3 and C4 in maternal sera and quantified the placental mRNA expression of complement regulatory proteins CD46, CD55 and CD59. A significantly (p < 0.03) higher incidence of C4d deposition was observed in placentas from women with preeclampsia compared with uncomplicated pregnancies, both OD and autologous. The level of complement factors in serum did not differ between the groups. Children born in the autologous preeclampsia group were significantly lower in birth weight (p < 10th percentile) compared with the preeclamptic OD group. In addition, the placental mRNA expression level of complement regulatory proteins was significantly lower in uncomplicated and preeclamptic OD compared with the autologous pregnancies. In line with autologous preeclampsia pregnancies, there is excessive activation of complement in preeclamptic OD pregnancies. However, in contrast to autologous pregnancies this is not associated with counterbalancing upregulation of complement regulatory proteins. Furthermore, C4d deposition in OD pregnancies is not related to the severity of preeclampsia, suggesting another trigger or regulatory mechanism of placental C4d deposition in preeclamptic OD pregnancies.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  C4d; Complement activation; Complement regulatory proteins; Oocyte donation; Placenta; Preeclampsia

Mesh:

Substances:

Year:  2015        PMID: 25863695     DOI: 10.1016/j.jri.2015.03.004

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  5 in total

Review 1.  A new era in reproductive medicine: consequences of third-party oocyte donation for maternal and fetal health.

Authors:  Shigeru Saito; Yasushi Nakabayashi; Akitoshi Nakashima; Tomoko Shima; Osamu Yoshino
Journal:  Semin Immunopathol       Date:  2016-06-20       Impact factor: 9.623

Review 2.  Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy.

Authors:  Ai-Ris Y Collier; Laura A Smith; S Ananth Karumanchi
Journal:  Hum Immunol       Date:  2021-02-05       Impact factor: 2.850

3.  Relating the number of human leucocytes antigen mismatches to pregnancy complications in oocyte donation pregnancies: study protocol for a prospective multicentre cohort study (DONOR study).

Authors:  Kim van Bentem; Eileen Lashley; Manon Bos; Michael Eikmans; Sebastiaan Heidt; Frans Claas; Saskia le Cessie; Marie-Louise van der Hoorn
Journal:  BMJ Open       Date:  2019-07-24       Impact factor: 2.692

4.  What are the Predictive Factors for Preeclampsia in Oocyte Recipients?

Authors:  Céline Pimentel; Duros Solene; Jaffre Frédérique; Bouzille Guillaume; Leveque Jean; Le Lous Maëla
Journal:  J Hum Reprod Sci       Date:  2019-12-17

Review 5.  Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?

Authors:  E Pierik; Jelmer R Prins; Harry van Goor; Gustaaf A Dekker; Mohamed R Daha; Marc A J Seelen; Sicco A Scherjon
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.